Drug Patent Watch

JANUARY 9, 2025

Enter the Contract Development and Manufacturing Organization (CDMO) a lifeline for many startups looking to bring their innovative therapies to market. In 2017, small and medium-sized biotech companies accounted for 51% of FDA market approvals, while large pharma companies were the originators in only 28% of approvals[4].

Compliance

Codon

JUNE 5, 2025

The treatment, now known as Casgevy, became the first CRISPR-based therapy to gain FDA approval, in 2023. Researchers have since discovered variants of the protein with additional useful qualities. Researchers have also discovered a slew of small Cas9s — some less than half the size of the S.

DNA

Drug Target Review

NOVEMBER 7, 2024

In these conditions, the goal of therapy is typically to suppress or mitigate immune activity. Understanding the intricate role of PSGL-1 in immune-cell recruitment and activation is essential for developing targeted therapies aimed at modulating immune responses in various inflammatory and autoimmune disorders.

Disease

New Drug Approvals

JULY 8, 2025

Clinical Trials: Pritelivir is currently in phase II clinical trials, with ongoing research into its effectiveness and safety. Research and Development: Pritelivir is being developed by AiCuris Anti-infective Cures, building upon research from Bayer. PAPER By: Carta, Fabrizio ; et al.

Virus

BioPharma Drive: Drug Pricing

JUNE 27, 2025

Daily Dive M-F Commercialization Weekly Every Wednesday Gene Therapy Weekly Every Thursday Emerging Biotech Weekly Every Tuesday By signing up to receive our newsletter, you agree to our Terms of Use and Privacy Policy. BCMA and CD19 are the protein targets of the seven approved CAR-T therapies. You can unsubscribe at anytime.

Therapies

Codon

JULY 14, 2025

My goal is not only to tell the story of a pharmaceutical staple but to share what my decades-long work in evidence synthesis in epidemiology has taught me about researching scientific history. The origins of aspirin make a good subject for exposing the challenges of scientific research for a couple of reasons.

Treatment

New Drug Approvals

JULY 18, 2025

SYN [link] According to the inventor’s research and understanding, at present, the synthesis of azvudine mainly includes the following methods according to different raw materials: 1. 8] It received its current name in 2009, when researchers at Roche independently discovered it as a Hep C RNA polymerase inhibitor in vitro. [4]

RNA

Drug Target Review

NOVEMBER 17, 2023

They do not induce ‘graft versus host’ disease when transplanted for allogeneic therapy and there appears little sign of immune rejection. Peripheral blood NK cells have been used in allogeneic cancer therapies and shown to be safe. CAR-NK cell trials only commenced in 2017 and most are still recruiting patients.

Therapies

The Pharma Data

JULY 2, 2025

LupinLife was originally launched in 2017 as Lupin’s dedicated consumer healthcare arm. across multiple therapy areas, including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women’s health.

Pharmaceuticals

Drug Target Review

SEPTEMBER 22, 2023

Organoid technologies are becoming an invaluable solution for preclinical research, with the ability to augment the development of personalised medicine, drug discovery and gene therapies. The derived drug was given to both patients, to which researchers report the patients saw significant improvement. Elsevier; 2020.

Clinical Research

Drug Target Review

FEBRUARY 28, 2024

Over the past 25 years, T-cell therapies have gained significant ground in the treatment of cancer. Preclinical research on γδ T cells has made great strides since the cells were first identified in the 1980s, with γδ T-cell therapies from several companies, including IN8bio, now in or nearing clinical trials for various cancers.

Therapies

Drug Target Review

JUNE 19, 2024

The mission of Lineage Cell Therapeutics is to deliver on some of the early promises of cell therapy. Cell therapy as a concept is a wonderful idea, but many of the early efforts never generated the kind of clinical data that gets people excited and leads to new medicines. Hearing aids also have all sorts of deficits.

Therapies

Broad Institute

OCTOBER 4, 2023

Researchers from the Tumor Immunotherapy Discovery Engine ( TIDE ) at the Broad Institute of MIT and Harvard, AbbVie, and Calico Life Sciences report that the molecule simultaneously makes tumors more sensitive to immune attack and boosts the activity of immune cells to fight tumors in mice.

Small Molecule

Drug Target Review

AUGUST 29, 2024

What potential advantages does the CD5 modulation strategy offer over traditional CAR-T therapies? MR : Chimeric antigen receptor T-cell (CAR-T) therapy is very effective in treating patients with B-cell lymphoma, leukemia, and multiple myeloma, where we have six FDA-approved drugs.

Therapies

Advarra

JUNE 12, 2023

Gene therapy research is exciting and full of promise, but because of the risks involved, it’s also highly regulated, requiring an institutional biosafety committee (IBC) to provide additional oversight and risk assessment. IRBs are tasked with protecting research subject’s rights and welfare. What Does an IBC Review?

Engineering

The Pharma Data

AUGUST 5, 2020

. Novartis has revealed positive results from a phase 2 study of its CAR-T therapy Kymriah (tisagenlecleucel) in patients with relapsed or refractory follicular lymphoma. The therapy is a one-time treatment created individually for each patient using their own T cells.

Therapies

The Pharma Data

JANUARY 4, 2021

Collaboration with Biogen to develop gene therapy for an undisclosed target to treat inherited eye disease, plus option for additional target. 05, 2021 (GLOBE NEWSWIRE) — ViGeneron GmbH , a gene therapy company, today announced a global collaboration and licensing agreement with Biogen Inc. MUNICH, Germany, Jan.

Therapies

The Pharma Data

JANUARY 11, 2021

Pfizer has started dosing in a phase 3 study evaluating its investigational gene therapy, PF-06939926, in young male patients with Duchenne muscular dystrophy (DMD). The agency previously granted the gene therapy Orphan Drug and Rare Pediatric Disease designations in 2017. Source link.

Therapies

The Pharma Data

JANUARY 17, 2021

The companies will evaluate ViGeneron’s proprietary, intravitreally injected vgAAV vectors for delivering a novel therapeutic protein to develop a gene therapy treatment for a highly prevalent eye disease. There is significant unmet medical need for a sustained therapy to treat eye diseases. MUNICH, Germany, Jan. About ViGeneron.

Therapies

Drug Target Review

DECEMBER 5, 2024

Viral vectors have been crucial in transforming the gene therapy landscape due to their natural ability to infect cells. 1 In 2017, the US Food and Drug Administration (FDA) approved the first AAV-based gene replacement therapy (Luxturna), for Leber congenital amaurosis type 2.

Therapies

Drug Target Review

JANUARY 25, 2024

Researchers from the Cleveland Clinic, led by Dr Ofer Reizes and Dr Justin Lathia, have developed a therapeutic peptide that disrupts the molecular processes behind aggressive cancer cell growth. 3 Therefore, the researchers aimed to disrupt this complex to limit the cancerous properties of the cells. Journal of Biomedical Science.

Treatment

Drug Target Review

AUGUST 16, 2023

Utilising just 15ul of patient serum samples, the researchers tested it with silver nanowires for various cancer types, capturing molecular vibrational changes indicative of altered physiology and pathology in cancer samples. References 1. Jillian Phallen. Direct detection of early-stage cancers using circulating tumor DNA.

DNA

KIF1A

JUNE 17, 2023

Dylan Verden of KIF1A.ORG summarizes newly published KIF1A-related research and highlights progress in rare disease research and therapeutic development. The researchers assessed KIF1A’s speed, distribution, and ability to transport both small and large cargo across these 16 mutations. What’s a pre-print? .

Laboratories

Drug Target Review

JULY 10, 2023

Despite decades of research and development, there are currently no drugs that can prevent or cure these diseases and only limited options for symptomatic relief. This deeper understanding has enabled the development of numerous potentially breakthrough therapies, which are currently being tested in the clinic. 2017 Dec 11;9(1).

Research

Drug Target Review

OCTOBER 17, 2023

Diagnosis and therapy The study’s findings have promising implications for liver cancer therapy. This research was published in Cell. 2017 July [cited 2023 October 9]; 3(2):45-51. “Our immune cells depend on arginine to function properly,” Mossman explained. References 1 Krafts K, Ray SD, Yang N. Cell Proliferation.

Regulations

Drug Target Review

FEBRUARY 2, 2024

What specific limitations in mirroring diseases in humans are commonly observed when using animal models for preclinical research? We foresee that the use of animal models to assess efficacy and eventually toxicity will decrease, reducing the number of animals sacrificed for research. Prior to Organovo, Mr.

Drugs

The Pharma Data

DECEMBER 21, 2020

Legend will receive $75 million from J&J as a clinical development-based milestone payment, per a 2017 collaboration pact. Cilta-cel also won a Breakthrough Therapy designation in China in August. Source link.

Therapies

Creative Biolabs

JUNE 29, 2023

The development of GPCR research tools and antibody drugs in the form of single domain antibodies is a major trend in the future. This provides new tools for diagnostic and therapeutic research in the field of neurology. It has been widely used in various studies targeting GPCR family members. Roth et al.,

Therapies

Drug Target Review

SEPTEMBER 26, 2023

Human derived induced pluripotent stem cells (hiPSCs) have revolutionised research and are increasingly used for toxicology screening and disease modelling. Early detection of neurotoxicity induced by potential new therapies is a major challenge, and hiPSC-neuronal cells may provide a solution. 2017 Jan;155(1):234–47.

Drugs

Drug Target Review

AUGUST 24, 2023

Neutralising GDF-15 with CatalYm’s anti-GDF-15 antibody visugromab was shown to reverse its inhibitory effects and to re-sensitise tumours to anti-PD-1 treatment, achieving commensurate survival benefit of anti-GDF-15-anti-PD-1 combination therapy in vivo. in North America) in late 2017. Cancer Immunology Research.

Treatment

New Drug Approvals

NOVEMBER 13, 2023

Vodobatinib can be used for chronic myeloid leukemia (CML) research. Vodobatinib can be used for chronic myeloid leukemia (CML) research [1] [2]. VODOBATINIB 1388803-90-4 Molecular Weight 453.92 Vodobatinib exhibits activity against most BCR-ABL1 point mutants, and has no activity against BCR-ABL1T315I.

Treatment

Drug Target Review

MAY 23, 2023

Therapies developed in recent decades have transformed the treatment of IBD, making hospitalisation and surgery less common. However, many patients respond poorly to corticosteroid treatment, or their immune system responds unfavourably to biological therapies, such as the development of autoimmune diseases.

Drugs

FDA Law Blog: Biosimilars

DECEMBER 4, 2023

A prescription not issued in the usual course of professional treatment or in legitimate, authorized research is not a prescription within the meaning of the CSA and the pharmacist knowingly filling it, along with the prescriber issuing it, is subject to penalties. 21 U.S.C. § 829; 21 C.F.R. Complaint ¶ 55. Complaint ¶ 58.

Pharmacy

Drug Target Review

MARCH 5, 2024

The first true test of my commitment came with my PhD in Biophysics as a scholar at the International Max-Planck Research School, specifically when I became pregnant with my first child in 2006. Could you share an example of a specific project or research that you have worked on and the impact it has had in your field?

Engineering

Drug Target Review

APRIL 3, 2024

Could you share an example of a specific project or research that you have worked on and the impact it has had in your field? Our company has identified a new role for Growth Differentiation Factor 15 (GDF-15) as a potent local immunosuppressor mediating cancer resistance to therapy.

Science

Drug Target Review

OCTOBER 25, 2024

At Johnson & Johnson, our differentiated Alzheimer’s disease research program is focused on leveraging the latest advancements in precision medicine, data science and digital health to help make earlier diagnosis an option and help treat the right patient with the right treatment at the right time.

Disease

New Drug Approvals

SEPTEMBER 13, 2024

19] As of 2016, aticaprant has reached phase II clinical trials as an augmentation to antidepressant therapy for treatment-resistant depression. [20] 21] In August 2017, it was announced that Cerecor had sold its rights to aticaprant to Janssen Pharmaceuticals. [22] Dhir A (January 2017). August 2017. nM vs. 24.0

Treatment